Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~* Subjects who have received dTpa vaccine or Td and pa vaccines in study 263855/004.~* A male or female subject, recruited 10 years after booster vaccination in study 263855/004.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* If the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must use adequate contraception for 30 days prior to vaccination and continue for 2 months after completion of the vaccination series.~* Written informed consent obtained from the subject.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.~* Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination or planned administration during the active study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Previous booster vaccination against tetanus, diphtheria or pertussis since the last dose received in study 263855/004.~* History of documented diphtheria, tetanus, or pertussis diseases.~* Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.~* Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.~* Occurrence of any of the following adverse event after a previous administration of a DTP vaccine :~  * hypersensitivity reaction to any component of the vaccine,~ * encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine,~ * fever \>= 40°C within 48 hours of vaccination not due to another identifiable cause,~ * collapse or shock-like state (hypotonic-hyporesponsiveness episode) within 48 hours of vaccination,~ * convulsions with or without fever, occurring within 3 days of vaccination.~* Acute disease at the time of enrolment.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions within 2 months after completion of the vaccination series.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- BOOSTRIX I GROUP (Type: EXPERIMENTAL): Subjects, who had received Boostrix™ vaccine in the primary study (263855/004), received one additional booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
- BOOSTRIX II GROUP (Type: EXPERIMENTAL): Subjects, who had received Wyeth's (formerly Lederle) combined adult diphtheria and tetanus vaccine and GSK Biologicals' acellular pertussis vaccine in the primary study (263855/004), received one booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).